Sign In
Last checked at 
24 Dec 2024 09:14
Bioventix plcĀ
Ā
("Bioventix" or "the Company")Ā
Ā
Director DealingĀ
Ā
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 23 December 2024 that on 23 December 2024 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 61 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at an average price of 3,273 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment planĀ ("DRIP").Ā
Ā
Following the Purchase, Bruce Hiscock has a beneficial interest in 1,174 Ordinary Shares, representing approximately 0.02 per cent. of the issued share capital of the Company.Ā
Ā
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.Ā
Ā
Ā
For further information please contact:Ā
Ā
Bioventix plcĀ Peter HarrisonĀ | Ā Chief Executive OfficerĀ | Tel: 01252 728 001Ā |
CavendishĀ Geoff Nash / Abigail Kelly Nigel Birks / Harriet WardĀ | Ā Corporate FinanceĀ ECMĀ | Tel: 020 7220 0500Ā |
Ā
Ā
Ā
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with themĀ
Ā
Ā
1Ā | Details of the person discharging managerial responsibilities / person closely associatedĀ | |
a)Ā | NameĀ | Bruce HiscockĀ |
2.Ā | Reason for the NotificationĀ | |
a)Ā | Position/statusĀ | Chief Financial OfficerĀ |
b)Ā | Initial notification/AmendmentĀ | Initial notificationĀ |
3.Ā | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitorĀ | |
a)Ā | NameĀ | Bioventix PlcĀ |
b)Ā | LEIĀ | 213800225MHX7LZQY108Ā |
4.Ā | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conductedĀ | |
a)Ā | Description of the Financial instrument, type of instrumentĀ | Ordinary Shares of 5 pence eachĀ |
Identification codeĀ | GB00B4QVDF07Ā | |
b)Ā | Nature of the transactionĀ | Purchase of Ordinary SharesĀ |
c)Ā | Price(s) and volume(s)Ā | 61 Ordinary SharesĀ 3,273 penceĀ |
d)Ā | Aggregated information:Ā Ā Ā· Aggregated volumeĀ Ā Ā· PriceĀ | Purchase of 61 Ordinary Shares at 3,273 pence eachĀ |
e)Ā | Date of the transactionĀ | 23 December 2024Ā |
f)Ā | Place of the transactionĀ | London Stock Exchange, AIM Market (XLON)Ā |
Ā
Ā
Follow the stocks
